Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTSO NYSE:MLSS NASDAQ:NMTC NASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.46-5.9%$0.56$0.44▼$1.39$30.64M1.35163,128 shs77,811 shsMLSSMilestone Scientific$0.42-4.3%$0.34$0.22▼$0.92$36.58M1.041.33 million shs137,669 shsNMTCNeuroOne Medical Technologies$3.44-1.1%$4.29$3.27▼$6.96$30M0.5134,629 shs20,858 shsVVOSVivos Therapeutics$0.86+24.8%$0.90$0.55▼$7.95$9.62M6.1133,333 shs67.97 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents-5.94%-6.50%-19.47%-42.48%-54.10%MLSSMilestone Scientific-4.31%+7.31%+2.95%+47.85%-54.34%NMTCNeuroOne Medical Technologies-1.15%-3.10%-20.00%-31.75%-4.78%VVOSVivos Therapeutics+24.84%+23.50%+20.09%-35.00%-63.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.46-5.9%$0.56$0.44▼$1.39$30.64M1.35163,128 shs77,811 shsMLSSMilestone Scientific$0.42-4.3%$0.34$0.22▼$0.92$36.58M1.041.33 million shs137,669 shsNMTCNeuroOne Medical Technologies$3.44-1.1%$4.29$3.27▼$6.96$30M0.5134,629 shs20,858 shsVVOSVivos Therapeutics$0.86+24.8%$0.90$0.55▼$7.95$9.62M6.1133,333 shs67.97 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents-5.94%-6.50%-19.47%-42.48%-54.10%MLSSMilestone Scientific-4.31%+7.31%+2.95%+47.85%-54.34%NMTCNeuroOne Medical Technologies-1.15%-3.10%-20.00%-31.75%-4.78%VVOSVivos Therapeutics+24.84%+23.50%+20.09%-35.00%-63.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSOCytosorbents 2.00Hold$5.381,071.02% UpsideMLSSMilestone Scientific 3.00Buy$1.00140.79% UpsideNMTCNeuroOne Medical Technologies 2.40Hold$11.67239.15% UpsideVVOSVivos Therapeutics 2.25Hold$2.80223.89% UpsideCurrent Analyst Ratings BreakdownLatest VVOS, MLSS, NMTC, and CTSO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026VVOSVivos Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $3.105/13/2026NMTCNeuroOne Medical Technologies LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.60 ➝ $8.005/11/2026NMTCNeuroOne Medical Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/22/2026VVOSVivos Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.50 ➝ $3.004/20/2026VVOSVivos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026VVOSVivos Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $2.504/8/2026CTSOCytosorbents Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/26/2026CTSOCytosorbents D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.003/13/2026NMTCNeuroOne Medical Technologies Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSOCytosorbents$37.06M0.78N/AN/A$0.09 per share5.10MLSSMilestone Scientific$8.90M4.11N/AN/A$0.11 per share3.78NMTCNeuroOne Medical Technologies$12.10M2.45N/AN/A$0.85 per share4.05VVOSVivos Therapeutics$17.44M0.69N/AN/A($0.16) per share-5.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSOCytosorbents-$8.20M-$0.19N/A15.30N/A-31.85%-235.57%-37.88%8/6/2026 (Estimated)MLSSMilestone Scientific-$6.93M-$0.05N/AN/AN/A-52.01%-60.26%-40.23%N/ANMTCNeuroOne Medical Technologies-$3.61M-$0.85N/AN/AN/A-68.35%-98.33%-69.85%8/13/2026 (Estimated)VVOSVivos Therapeutics-$21.17M-$2.14N/AN/AN/A-127.70%-2,325.64%-98.12%8/18/2026 (Estimated)Latest VVOS, MLSS, NMTC, and CTSO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026VVOSVivos Therapeutics-$0.45-$0.52-$0.07-$0.52$4.35 million$5.14 million5/13/2026Q1 2026CTSOCytosorbents-$0.06-$0.08-$0.02-$0.08$9.40 million$8.86 million5/12/2026Q2 2026NMTCNeuroOne Medical Technologies-$0.2267-$0.25-$0.0233-$0.25$2.58 million$2.39 million4/15/2026Q4 2025VVOSVivos Therapeutics-$0.4950-$0.58-$0.0850-$0.58$7.10 million$3.82 million3/25/2026Q4 2025CTSOCytosorbents-$0.05-$0.09-$0.04-$0.09$9.22 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTSOCytosorbentsN/AN/AN/AN/AN/AMLSSMilestone ScientificN/AN/AN/AN/AN/ANMTCNeuroOne Medical TechnologiesN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSOCytosorbents4.701.090.81MLSSMilestone ScientificN/A2.851.86NMTCNeuroOne Medical TechnologiesN/A4.383.28VVOSVivos Therapeutics3.310.270.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSOCytosorbents32.87%MLSSMilestone Scientific5.79%NMTCNeuroOne Medical Technologies16.07%VVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipCTSOCytosorbents7.30%MLSSMilestone Scientific12.51%NMTCNeuroOne Medical Technologies11.80%VVOSVivos Therapeutics2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSOCytosorbents22062.79 million58.21 millionOptionableMLSSMilestone Scientific3088.08 million58.61 millionOptionableNMTCNeuroOne Medical Technologies208.62 million7.60 millionOptionableVVOSVivos Therapeutics16013.90 million13.60 millionOptionableVVOS, MLSS, NMTC, and CTSO HeadlinesRecent News About These CompaniesVivos Therapeutics Announces Debt Exchange Agreement with Streeterville Capital to Strengthen Financial PositionJune 5 at 8:51 AM | quiverquant.comQVivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq ListingJune 5 at 8:45 AM | globenewswire.comVivos Therapeutics Inc (VVOS) Q1 2026 Earnings Call Highlights: Revenue Surges Amid Strategic ShiftsMay 29, 2026 | finance.yahoo.comVivos Therapeutics Balances Rapid Growth With Cash StrainMay 22, 2026 | tipranks.comVivos Therapeutics Earnings Call: Growth Meets Cash StrainMay 21, 2026 | tipranks.comVivos Therapeutics, Inc: Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational UpdateMay 21, 2026 | finanznachrichten.deVivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call TranscriptMay 21, 2026 | seekingalpha.comVivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational UpdateMay 20, 2026 | globenewswire.comVivos Therapeutics Delays Quarterly FilingMay 15, 2026 | tipranks.comAnalysts see 200%+ upside in these 3 high-risk stocks: here's why?May 9, 2026 | invezz.comIVivos Therapeutics (VVOS) price target decreased by 51.67% to 2.47April 29, 2026 | msn.comVivos Therapeutics Faces Nasdaq Listing Compliance ChallengesApril 22, 2026 | tipranks.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2025 Earnings Call TranscriptApril 17, 2026 | insidermonkey.comVivos Therapeutics Q4 Earnings Call HighlightsApril 17, 2026 | defenseworld.netDVivos Therapeutics Balances Growth Hopes With Cash StrainApril 16, 2026 | tipranks.comVivos targets cash flow positive operations by end of 2026 as it scales SO teams with $500,000+ monthly collections potentialApril 16, 2026 | seekingalpha.comVivos Therapeutics Inc (VVOS) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ...April 16, 2026 | finance.yahoo.comVivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call TranscriptApril 15, 2026 | seekingalpha.comVivos Therapeutics Reports Full Year 2025 Financial ResultsApril 15, 2026 | globenewswire.comVivos Therapeutics, Inc. to Release Full Year 2025 Financial Results and Conduct Conference Call on April 15, 2026April 15, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVVOS, MLSS, NMTC, and CTSO Company DescriptionsCytosorbents NASDAQ:CTSO$0.46 -0.03 (-5.94%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.46 0.00 (0.00%) As of 06/5/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Milestone Scientific NYSE:MLSS$0.42 -0.02 (-4.31%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.42 +0.00 (+0.17%) As of 06/5/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Milestone Scientific Inc., a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. In addition, the company offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances, and disposable injection handpiece for the tactile control during the injection. Further, it provides CompuFlo Epidural, a computer-controlled anesthesia system for use in various medical applications. Additionally, the company offers company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Roseland, New Jersey.NeuroOne Medical Technologies NASDAQ:NMTC$3.44 -0.04 (-1.15%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$3.52 +0.08 (+2.44%) As of 06/5/2026 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.Vivos Therapeutics NASDAQ:VVOS$0.86 +0.17 (+24.84%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.82 -0.05 (-5.73%) As of 06/5/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
